Adjuvant or neoadjuvant chemotherapy for NSCLC

Journal of Thoracic Disease

Volumn 6, Issue SUPPL.2, 2014, Pages

  McElnay, Philip ^a   Lim, Eric ^b  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Chemotherapy; Lung cancer; Neoadjuvant therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DRUG RESPONSE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LUNG SURGERY; META ANALYSIS (TOPIC); OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 84904762009     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.04.26     Document Type: Review

References (13)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. D'Addario G, Felip E; ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:68-70.
3. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi89-98.
4. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage nonsmall- cell lung cancer. J Clin Oncol 2010;28:3138-45.
5. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
6. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
7. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-37.
8. Ball D, Mitchell A, Giroux D, et al. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer. J Thorac Oncol 2013;8:315-21.
9. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012;30:172-8.
10. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014;383:1561-71.
11. Lim E, Harris G, Patel A, et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2009;4:1380-8.
12. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage nonsmall- cell lung cancer. J Clin Oncol 2010;28:3138-45.
13. Chaft JE, Rusch V, Ginsberg MS, et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous nonsmall- cell lung cancers. J Thorac Oncol 2013;8:1084-90.